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75% males) had been exposed to clopidogrel in the 7 days prior to surgery and 117 (mean age 66.8 years; 73.5% males) had not. No sample size or power calculations were reported.
Study design
The study was of a single-centre retrospective cohort design. The patients were followed up for the duration of their hospital stay. The nature of the study meant that there was no loss to follow-up and it was not possible to blind to treatment group.
Analysis of effectiveness
The following health outcomes were assessed: The two patient groups were comparable in terms of age, gender, body surface area, haematocrit, creatinine and whether or not they had congestive heart failure. Patients who had been exposed to clopidogrel in the 7 days prior to surgery were more likely to have angina than those not exposed (56.2% versus 40.2%; p=0.058), and to have been operated on urgently (within 24 hours) (33.3% versus 14.5%; p=0.0095). No adjustment for these differences appears to have been made in the analysis. In addition, patients exposed to clopidogrel were significantly more likely to have preoperative aspirin exposure than patients not exposed to clopidogrel (87.5% versus 43%; p<0.0001). There was no significant difference between control patients with and without recent aspirin exposure.
Effectiveness results
The following health outcomes were statistically different between the two patient groups: the mean chest tube output at 8 hours, 864 mL in the clopidogrel group versus 492 mL in the control group, (p=0.001); the mean chest tube output at 24 hours, 1,384 mL in the clopidogrel group versus 801 mL in the control group, (p=0.001); the percentage of patients transfused any blood product, 89.6% of the clopidogrel group versus 53.8% of the control group, (p<0.0001); the percentage of patients transfused red blood cells, 85.4% of the clopidogrel group versus 50.4% of the control group, (p<0.0001); the percentage of patients transfused platelets, 50% of the clopidogrel group versus 14.5% of the control group,
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Clinical conclusions
The author concluded that improvements in blood use and clinical outcomes were documented within 3 months after the evidence-based clinical practice guideline for Clopidogrel Exposure in Cardiac Surgery Patients had been implemented. .
Measure of benefits used in the economic analysis
No measure of benefits was used in the economic analysis. In effect, the author carried out a cost-consequences analysis.
Direct costs
Hospital costs were included in this study. The cost data represented actual data and were collected from the hospital's central costing database. The cost components combined to derive a total cost were the laboratory/blood, critical care, medical/surgical, respiratory therapy/physiotherapy, supplies, pharmacy, operating room and anaesthesia, physical therapy, radiology and other costs. The resources used and the unit costs were not reported separately. The cost data referred to the period between January 1999 and 2000, but no price year was reported. Discounting was not undertaken as the costs were incurred during less than two years.
Statistical analysis of costs
The difference between the costs was tested using the t-test. The mean total costs were reported.
Indirect Costs
No indirect costs were included in the study.
Currency

US dollars ($).
Sensitivity analysis
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No sensitivity analysis was undertaken.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The mean total costs were $20,304 for the group exposed to clopidogrel in the 7 days prior to surgery and $17,624 for those in the comparator group, (p=0.1936). The only cost component that was statistically different between the two groups was laboratory and blood costs, $1,699 for the clopidogrel group versus $1,018 for the comparator group, (p=0.0135).
The acute care costs averaged $2,680 more for patients who received clopidogrel, (p=0.1936).
Synthesis of costs and benefits
The costs and benefits were not combined.
Authors' conclusions
Exposure to clopidogrel prior to coronary artery bypass graft (CABG) surgery had a negative affect on postoperative bleeding and length of stay (LOS). Reduced use of clopidogrel prior to surgery might be cost-saving, given the intensity of resource use with acute haemorrhage and the expense of blood products.
CRD COMMENTARY -Selection of comparators
The author did not provide an explicit justification for her choice of the comparator. However, it did represent a donothing approach. You should consider how this relates to current practice in your own setting.
Validity of estimate of measure of effectiveness
The measure of the clinical implications of using clopidogrel prior to CABG surgery was taken from a retrospective cohort study. This was appropriate to the study question, although it provides a potentially biased assessment. The retrospective nature of the study meant that patient allocation to the clopidogrel group or the non clopidogrel group will have been subject to a number of factors that can no longer be assessed. The two patient groups were shown to not be comparable in terms of the prevalence of angina and whether or not they were operated on urgently. The analysis did not adjust for these factors, thus it was not possible to assess their impact on the study findings. A randomised controlled trial would have provided a more robust assessment of the true impact of clopidogrel on postoperative bleeding and recovery. The author did not compare the characteristics of her study sample with the characteristics of the study population. This means that it was not possible to assess the extent to which the study sample represents the study population.
Validity of estimate of measure of benefit
No measure of benefit was used in the economic evaluation since, in effect, a cost-consequences analysis was undertaken.
Validity of estimate of costs
The author did not report the economic perspective used, but it appears to have been that of a hospital. All appropriate costs appear to have been included in the analysis. Resource use and the unit costs were not reported separately. This, along with that fact that costs were taken from the author's own setting rather than a nationally applicable cost framework, reduces the generalisability of the study findings. The lack of a clear price year further limits the study and prevents any future reflation exercises. No statistical analysis of the resource use data was performed, although the cost
